Sign up to our newsletter Subscribe
Sign up to our newsletter Subscribe
The 2017 iHEA congress will be held in Boston, 7th-11th July 2017. Members of the OHE team will be attending and participating in the conference, and would welcome the opportunity to meet with you. The 2017 biennial congress of the…
The 2017 iHEA congress will be held in Boston, 7th-11th July 2017. Members of the OHE team will be attending and participating in the conference, and would welcome the opportunity to meet with you.
The 2017 biennial congress of the International Health Economics Association (iHEA) will be held in Boston, 7th-11th July. Members of the OHE team will be attending and participating in the conference, and would welcome the opportunity to meet with you.
You will find members of the OHE team presenting at the following sessions:
Special Invited Session: Adjusting for Differential Item Functioning in the EQ-5D-5L Using Externally-Collected Vignettes
OHE Presenter: Paula Lorgelly
Time & Date: Monday 10th July, 11:45
Paula will discuss how anchoring vignettes can be used to adjust for reporting heterogeneity in the EQ-5D-5L. The paper builds on previous research and shows that vignettes collected external to the dataset of interest can be used to make adjustments therefore removing a degree of reporting bias in the EQ-5D. The approach shows the added value of vignettes to patient reported outcome measures like the EQ-5D as well as other self-reported health responses.
Presentation: Establishing a Fair Price for an Orphan Drug
OHE Presenter: Mikel Berdud
Time & Date: Tuesday 11th July, 11:30
Mikel will discuss and propose options for setting a fair price for an orphan drug. The presentation is based on the proposition that, although society would be willing to sacrifice some health gain overall to make treatments for some orphan diseases available, it would not tolerate a situation whereby manufacturers of these drugs made higher profits than those manufacturers of drugs for non-orphan conditions. That is, the rates of return from investments in developing orphan drugs should be no greater than the industry average, after adjustments for risk and any other relevant factors – i.e. fair to the manufacturer and fair to society. This presentation is based on work undertaken in collaboration with Prof. Mike Drummond (University of York) and Prof. Adrian Towse (OHE).
In addition, Paula Lorgelly, with Carl Ashe (University of Illinois), has organised a ‘Special Organised Session’ (akin to a mini plenary) on Value Frameworks: Current Initiatives and Future Directions. This session will be held on Monday 10th July at 10:00. The session will be live streamed for those unable to attend the conference.
For further information on any of these presentations please contact the OHE authors via our Meet the Team webpage.
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!